Veranova Moves Corporate Headquarters to Devens, Massachusetts

• Veranova has relocated its corporate headquarters to its Devens, Massachusetts facility.

• The site is undergoing a $30 million expansion to enhance ADC and high-potent API development and manufacturing capabilities.

Veranova has announced the relocation of its corporate headquarters to its Devens, Massachusetts facility, one of its key manufacturing and development sites. The move aligns with the company’s long-term strategy to strengthen its position as a leading partner for complex synthetic pharmaceuticals.

The Devens facility, strategically located near Boston’s pharmaceutical and biotech hub, is an FDA-approved site specializing in antibody-drug conjugates (ADCs), high-potency active pharmaceutical ingredients (APIs), phosphoramidites, and other complex small molecules. The site is currently undergoing a $30 million expansion to enhance its ADC and high-potent development and manufacturing capabilities.

The headquarters relocation is part of a broader multi-year growth strategy that spans Veranova’s global sites, including locations in West Deptford, New Jersey; North Andover, Massachusetts; Edinburgh, Scotland; and Cambridge, England.

As part of this transition, Veranova will exit its current headquarters office in Wayne, Pennsylvania. Employees based there will continue operations from a new location in Berwyn, Pennsylvania.